GELSYN-3 (hyaluronic acid) / Bioventus - LARVOL DELTA

Bioventus Agrees to Nationwide Contract with Cigna Commercial Plans for DUROLANE® and GELSYN-3® for Knee Osteoarthritis (GlobeNewswire) - "Bioventus Inc...has agreed to a nationwide contract with Cigna® commercial plans. Beginning July 1, 2022, Cigna® commercial plan members will have access to both DUROLANE and GELSYN-3, to treat knee osteoarthritis (OA) pain. DUROLANE, is a single-injection and GELSYN-3, is a three-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. Durolane will be exclusive to all Cigna patients while Gelsyn-3 will be one of two multi-injection HA products under contract."

Licensing / partnership • CNS Disorders • Musculoskeletal Diseases • Osteoarthritis • Pain

"$BVS Bioventus Agrees to Nationwide Contract with Cigna Commercial Plans for DUROLANE® and GELSYN-3® for Knee Osteoarthritis https://t.co/6BbyrMTYZQ" (@stock_titan)

Immunology • Osteoarthritis • Pain • Rheumatology

A Comprehensive Review of Viscosupplementation in Osteoarthritis of the Knee. (PubMed, Orthop Rev (Pavia)) - "Current treatment options include Hylan g-f-20, Sodium Hyaluronate preparations (Suparts Fx, Euflexxa, Gelsyn-3, Durolane, Hyalgen), single-use agents (Gel-One, Synvisc-One, Monovisc), and Hyaluronan (Orthovisc, Monovisc, Hymovic). VS effectively reduces pain, increases functionality, and delays surgery in the knee to treat osteoarthritis. While previous studies have demonstrated variable results, more evidence is becoming available generally supportive of the benefit of VS in the treatment of knee OA."

Journal • Review • Immunology • Inflammation • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology • NFKB1

Bioventus to Provide CVS Caremark with its Portfolio of Preferred Options for Knee Osteoarthritis Patients Seeking Pain Relief (Businesswire) - "Beginning January 1, 2021 Bioventus, a global leader in Innovations For Active Healing, will gain preferred access through the CVS Caremark Formulary, to DUROLANE®, GELSYN-3® and SUPARTZ FX®, for the treatment of knee osteoarthritis (OA) pain."

Reimbursement • CNS Disorders • Osteoarthritis • Pain

Bioventus to provide Blue Cross Blue Shield of Michigan with preferred options for knee osteoarthritis patients (Businesswire) - "Beginning January 1, 2020 Bioventus...has secured preferred access for Blue Cross Blue Shield of Michigan Medicare Advantage and Commercial patients to DUROLANE, GELSYN-3 and SUPARTZ FX to treat knee osteoarthritis (OA) pain....All three products are among the four preferred choices for hyaluronic acid coverage under the medical benefit for PPO, HMO, Medicare Plus Blue PPO and BCN Advantage plans."

Reimbursement

Bioventus launches new website for knee osteoarthritis pain relief information (Businesswire) - "In support of World Arthritis Day, which is celebrated every October 12 to raise awareness of arthritis, Bioventus...has launched a disease and product information website called OAKneePainRelief.com which combines information on knee osteoarthritis (OA) for both patients and health care providers (HCPs)....Injection treatments of HA-based products, such as DUROLANE®, GELSYN-3®, and SUPARTZ FX® help manage knee OA pain....'OAKneePainRelief.com connects them to an online ordering and bill paying portal and to BV360, an online hub providing dedicated support to our customers throughout the reimbursement process.'"

eHealth